FDA to Allow Generic Drugmakers to Make Label Changes Independent of Innovators

The FDA intends to publish a proposed rule allowing generic drugmakers to make changes to product labels independent of a brand-name manufacturer. The rule would empower generic companies to notify consumers about safety risks and concerns they become aware of, supporters say. In turn, it could potentially make generic drugmakers liable in court for failing to do so.
Drug Industry Daily